Preoperative mFOLFIRINOX versus PAXG for stage I–III resectable and borderline resectable pancreatic ductal adenocarcinoma (PACT-21 CASSANDRA): results of the first randomisation analysis of a randomised, open-label, 2 × 2 factorial phase 3 trial
Michele Reni, Marina Macchini, Giulia Orsi, Letizia Procaccio, Giuseppe Malleo, Catia Carconi, Ilario Giovanni Rapposelli, Katia Bencardino, Mario Scartozzi, Gianpaolo Balzano, Domenico Tamburrino, Barbara Merelli, Elisa Sperti, Giulio Belfiori, Nicole Liscia, Silvia Bozzarelli, Mariacristina Di Marco, Emiliano Tamburini, Michèle Milella, Sara Lonardi, Giorgio Ercolani, Michele Mazzola, Diego Palumbo, Valter Torri, Massimo Falconi
Topics & Concepts
MedicinePancreatic ductal adenocarcinomaStage (stratigraphy)Internal medicineOncologyAdenocarcinomaRadiologySurgeryFactorialRandomized controlled trialOverall survivalPancreatic carcinomaPhases of clinical researchClinical trialCarcinomaGastroenterologySurvival analysisPancreatic and Hepatic Oncology ResearchCholangiocarcinoma and Gallbladder Cancer StudiesEsophageal Cancer Research and Treatment